Trial Profile
Venous Thromboembolism Prophylaxis with Apixaban in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma Receiving Induction Therapy with an Immunomodulatory-Based Regimen
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2021
Price :
$35
*
At a glance
- Drugs Apixaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Therapeutic Use
- 10 Jun 2020 Planned End Date changed from 31 Jan 2022 to 31 Jul 2020.
- 10 Jun 2020 Planned primary completion date changed from 31 Jan 2022 to 31 Jul 2020.
- 01 Jun 2020 Status changed from active, no longer recruiting to discontinued.